Q-omics provides the consensus-scored RNASEL profile across patient tissues and cancer cell-line models. RNASEL expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNASEL is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RNASEL protein abundance shows 20,190 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, COAD, and BRCA as cancer lineages where RNASEL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASEL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASEL survival associations across molecular data types. RNASEL RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASEL RNA expression–survival associations across cancer types. High RNASEL expression shows unfavorable associations in LGG, UVM, ESCA and READ, but favorable associations in KIRC and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNASEL RNA expression.
This table summarizes RNASEL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RNASEL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASEL shows lower tumor expression in COAD, KICH, UCEC, READ, LUSC and THCA. The COAD box plot shows higher RNASEL RNA expression in normal versus tumor tissue (log2 FC = −1.384, t-test p < 0.001).
This table shows molecular features associated with RNASEL in patient tissues and cancer cell lines. In patient samples, RNASEL shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RNASEL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
